Synthetic Antibodies
Readiness
TRL 5 · SRL 4.5 · gap +0.5
Gap = technical readiness − societal readiness. Positive: the technology is ready and society is not. Negative: society wants it more than the technology can deliver.
Not scored. Watchlist entries do not enter any gradient.
Laboratory-designed molecules that bind a chosen target the way an antibody does, engineered rather than raised in an animal or selected from an immune response.
The advantages over conventional monoclonals are practical: smaller molecules that reach tissue a full antibody cannot, better stability so the cold chain is less demanding, faster design cycles, and no animal step. Combined with the protein-design entry above, the design half of this is being compressed considerably.
Technical readiness 5 against societal readiness 4.5 — a rare case where the technology slightly leads acceptance, and the reason is that the clinical and regulatory apparatus is built around antibodies as a known class. A molecule that does the job differently is evaluated as a new thing, at new-thing cost and new-thing timelines.
Common misconception: that these replace monoclonal antibodies. They extend the approach to targets and conditions monoclonals cannot serve, which is a larger prize than substitution.
What it does
mechanism — not yet written. Published as missing rather than hidden.